Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)

ClinicalTrials.gov ID: NCT04599933

Public ClinicalTrials.gov record NCT04599933. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (the NEAR-1 Study: Near Eye-vision Acuity Restoration)

Study identification

NCT ID
NCT04599933
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Orasis Pharmaceuticals Ltd.
Industry
Enrollment
309 participants

Conditions and interventions

Conditions

Interventions

  • CSF-1 Drug
  • Vehicle Drug

Drug

Eligibility (public fields only)

Age range
45 Years to 64 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 17, 2020
Primary completion
Feb 10, 2022
Completion
Feb 18, 2022
Last update posted
Apr 3, 2024

2020 – 2022

United States locations

U.S. sites
17
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
Orasis Investigative Site Sun City Arizona 85351
Orasis Investigative Site Glendale California 91204
Orasis Investigative Site Los Angeles California 90013
Orasis Investigative Site Fort Myers Florida 33901
Orasis Investigative Site Mt. Dora Florida 32757
Orasis Investigative Site Morrow Georgia 30260
Orasis Investigative Site Overland Park Kansas 66210
Orasis Investigative Site Louisville Kentucky 40206
Orasis Investigative Site Kansas City Missouri 64133
Orasis Investigative Site St Louis Missouri 63131
Orasis Investigative Site Henderson Nevada 89052
Orasis Investigative Site Elizabeth City North Carolina 27909
Orasis Investigative Site Cranberry Township Pennsylvania 16066
Orasis Investigative Site Wilkes-Barre Pennsylvania 18702
Orasis Investigative Site Rapid City South Dakota 57701
Orasis Investigative Site Memphis Tennessee 38119
Orasis Investigative Site El Paso Texas 79902

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04599933, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 3, 2024 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04599933 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →